Biodyne

Biodyne was founded in 1999 and listed on KOSDAQ in 2021 as a cervical cancer early-detection company built on Liquid Based Cytology (LBC) technology.

Its core technology is a proprietary patented 'Blowing' technique that spreads cells evenly onto slides without damage, applied in diagnostic devices and reagent kits sold under its own 'PATHPLORER' brand to markets including Japan, Russia, and Thailand.

As of 2025, LBC diagnostic reagent kits accounted for an overwhelming 89.5% of revenue, with device sales at 5.3% and other items making up the remaining 5.2%.

The company's central growth driver is a 20-year exclusive technology licensing and distribution agreement signed with Roche, the world's top in-vitro diagnostics company, in 2019, running through 2039 with automatic five-year renewals thereafter.

Under this agreement, Roche developed its own branded diagnostic device 'VENTANA SP400' using Biodyne's Blowing technology, which first launched in Japan in 2025. Royalties are structured as fixed amounts per device and per vial rather than tied to sales value.

New product pipeline includes the 'Earlypap' brush, which allows self-collection for combined STD, HPV, and cytology testing, and has received approval from both Korea's MFDS and the U.S. FDA.

In the competitive landscape, U.S.-based Hologic (ThinPrep) and Becton Dickinson have long split the LBC market, with Biodyne considered one of only three companies worldwide holding core LBC technology.

Biodyne posted a one-off strong performance in 2022 with revenue of KRW 12.21 billion and operating profit of KRW 6.68 billion (54.7% margin) on the back of a large upfront payment and milestone from Roche, but then swung to two consecutive years of losses amid a revenue gap tied to the contract: 2023 (revenue KRW 4.09 billion, operating loss KRW 2.05 billion) and 2024 (revenue KRW 5.27 billion, operating loss KRW 1.73 billion).

In 2025, revenue rose to KRW 7.03 billion with operating profit of KRW 652 million (9.3% margin) and owner net income of KRW 852 million, marking a return to profitability.

Quarterly results were volatile: Q2 2025 operating profit was a solid KRW 299 million on revenue of KRW 1.79 billion, while Q3 2025 saw revenue plunge to KRW 859 million with an operating loss of KRW 383 million, though net income stayed marginally positive at KRW 13 million.

Mirae Asset Securities stated in a March 2026 report that it estimated Q4 2025 revenue at KRW 3.5 billion (up 145% year-on-year) on rising cervical cancer test volumes, with operating profit estimated at KRW 1.3 billion (swing to profit, 36.7% margin) — a figure that should be noted as an analyst estimate rather than a confirmed disclosure.

However, confirmed Q1 2026 (revenue KRW 867 million, operating loss KRW 403 million, net income KRW 155 million) and Q2 2026 (revenue KRW 587 million, operating loss KRW 681 million, net loss KRW 323 million) results instead showed declining revenue and widening operating losses.

This trajectory diverges substantially from Mirae Asset's own full-year 2026 forecast issued around the same time (revenue KRW 11.6 billion, operating profit KRW 3.0 billion, 26.1% margin), suggesting royalty revenue recognition is running behind market expectations.

On the balance sheet side, the debt ratio has stayed very low, around 3% or less each year, and operating cash flow remained positive throughout 2022-2025.

Ultimately, the timing of when Roche-related royalties are substantially reflected in results remains the key variable for judging the company's future earnings path.

The cervical cancer early-detection market is in a structural growth phase as the World Health Organization pushes a campaign to raise the screening rate, currently below 40%, to 70% by 2030. Industry estimates put the related diagnostics market at roughly KRW 16 trillion by 2030.

In the competitive landscape, U.S.-based Hologic's ThinPrep has held roughly 60% share of the cytology testing market, with Becton Dickinson following behind. Biodyne is considered one of only three companies worldwide, alongside these two, holding core LBC technology.

Roche previously lacked its own cell-smearing technology and relied on partnerships with competitors, but adopting Biodyne's Blowing technology allowed it to offer the full cervical cancer screening process — HPV molecular testing plus cytology — under its own brand.

Roche's VENTANA SP400 launched in Japan in 2025 and saw its installed base grow more than 55% within six months, and Roche has disclosed plans to expand the launch to roughly 40 countries across Europe, North America, Latin America, and Asia during 2026.

A U.S. launch reportedly requires separate procedures and may lag, and the pace of country-by-country rollout remains a variable that determines the timing of royalty recognition.

In terms of industry cycle positioning, Biodyne sits at a transition point, shifting its center of gravity from own-brand revenue growth toward royalty revenue growth via the Roche partnership.

Roche has stated that following its 2025 Japan launch, it plans to expand VENTANA SP400 launches to roughly 40 countries across Europe, North America, Latin America, and Asia during 2026.

In this process, Biodyne will progressively collect fixed royalties per device and per vial, with some industry estimates suggesting royalties could grow to as much as KRW 120 billion annually within three to four years.

The new product pipeline includes the 'Earlypap' brush for combined self-collection of cervical cytology, HPV, and STD samples, though the clinical paper publication required for CE certification ahead of a European launch has been delayed beyond the original schedule.

In October 2025, the company decided on a new KRW 8 billion investment to build a production facility in Vietnam, aiming to expand mid- to long-term manufacturing capacity.

The Roche partnership is not limited to cervical cancer; there is discussion that if Roche applies Blowing technology to its cytology-based immunodiagnostic technology (such as 'CINtec PLUS'), collaboration could extend into non-gynecological areas.

Mirae Asset Securities projected in a March 2026 report — citing the ramp-up of royalty revenue and operating leverage — full-year 2026 revenue of KRW 11.6 billion and operating profit of KRW 3.0 billion (26.1% margin), but confirmed first-half results fell well short of that forecast, making second-half disclosures an important validation window.

Ultimately, when and how much royalty revenue is reflected will be the key variable determining the company's future earnings trajectory.